Abstract:Background The X-linked inhibitor of apoptosis protein (XIAP) is a well-known potent apoptosis suppressor and also participates in cancer cell biological behaviors, therefore attracting great attentions as a potential antineoplastic therapeutic target for past years. Anti-IAP therapy is reported to be closely related to epidermal growth factor receptor (EGFR) expression level. However, whether and how XIAP modulates EGFR expression remains largely unknown. Methods Human XIAP was knockdown with short-hairpin RNA in two different bladder cancer cell lines, T24T and UMUC3. Two XIAP mutants, XIAP ∆BIR (deletion of N-terminal three BIR domains) and XIAP ∆RING (deletion of C-terminal RING domain and keeping the function of BIR domains), were generated to determine which domain is involved in regulating EGFR. Results We found here that lacking of XIAP expression resulted in a remarkable suppression of EGFR expression, consequently leading to the deficiency of anchorage-independent cell growth. Further study demonstrated that BIR domain of XIAP was crucial for regulating the EGFR translation by suppressing the transcription and expression of miR-200a. Mechanistic studies indicated that BIR domain activated the protein phosphatase 2 (PP2A) activity by decreasing the phosphorylation of PP2A at Tyr307 in its catalytic subunit, PP2A-C. Such activated PP2A prevented the deviant phosphorylation and activation of MAPK kinases/MAPKs, their downstream effector c-Jun, and in turn inhibiting transcription of c-Jun-regulated the miR-200a. Conclusions Our study uncovered a novel function of BIR domain of XIAP in regulating the EGFR translation, providing significant insight into the understanding of the XIAP overexpression in the cancer development and progression, further offering a new theoretical support for using XIAP BIR domain and EGFR as targets for cancer therapy.

Zbtb38 inhibits apoptosis by transcriptionally regulating XIAP expression

XIAP Facilitates Breast and Colon Carcinoma Growth Via Promotion of P62 Depletion Through Ubiquitination-Dependent Proteasomal Degradation

Distinct Domains for Anti- and Pro-apoptotic Activities of IEX-1

XIAP inhibits autophagy via XIAP-Mdm2-p53 signalling.

Zinc Finger Protein 831 Promotes Apoptosis and Enhances Chemosensitivity in Breast Cancer by Acting As a Novel Transcriptional Repressor Targeting the STAT3/Bcl2 Signaling Pathway.

XIAP BIR Domain Suppresses Mir-200A Expression and Subsequently Promotes EGFR Protein Translation and Anchorage-Independent Growth of Bladder Cancer Cell

Transcriptome Profiling Reveals Inhibitory Effect of Down-regulated ZBTB38 gene on the Transcriptional Regulation of Tumor Cells Proliferation

Influence of Apoptin on Up-Regulation of the Expression of Bad and Bax

TFIIS.h, a New Target of P53, Regulates Transcription Efficiency of Pro-Apoptotic Bax Gene

X-linked Inhibitor of Apoptosis Protein (XIAP) Regulation of Cyclin D1 Protein Expression and Cancer Cell Anchorage-independent Growth via Its E3 Ligase-mediated Protein Phosphatase 2A/c-Jun Axis

Regulation of XIAP Turnover Reveals a Role for USP11 in Promotion of Tumorigenesis

X-linked inhibitor of apoptosis protein (XIAP) lacking RING domain localizes to the nuclear and promotes cancer cell anchorage-independent growth by targeting the E2F1/Cyclin E axis.

ZBP-89-induced apoptosis is p53-independent and requires JNK

A ZBP1 isoform blocks ZBP1-mediated cell death

Tumor suppressive BTB/POZ zinc-finger protein ZBTB28 inhibits oncogenic BCL6/ZBTB27 signaling to maintain p53 transcription in multiple carcinogenesis.

XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification.

Regulation of Xaf1 Expression in Human Colon Cancer Cell by Interferon Beta: Activation by the Transcription Regulator Stat1

XIAP underlies apoptosis resistance of renal cell carcinoma cells

XIAP Induces NF-κB Activation via the BIR1/TAB1 Interaction and BIR1 Dimerization

Characterization of the anti-apoptotic mechanism of Bcl-B

BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2.